Mass production and use of aspirin began in the 19th century, but the drug is widely used today. Many know it as a means to relieve headaches, and clinical antiplatelet properties of aspirin in the treatment of cardiovascular diseases. Despite the long history of the drug, he still becomes the object of clinical trials that may expand the scope of its application.
For example, recently it became clear that certain groups of patients, aspirin reduces the risk of developing esophageal cancer. British scientists led by Janus Jankowski (Jankowski Janusz) presented their research at the meeting this weekend of the conference of the American society of Oncology (ASCO 2018 Annual Meeteng). They are appreciated, how effective will adding aspirin to the proton pump inhibitor esomeprazole for the prevention of esophageal cancer in patients with Barrett’s esophagus.
The study involved 2563 patients with a diagnosis of “Barrett’s esophagus”. Researchers have identified 4 groups corresponding combinations of high and low doses of therapy with esomeprazole with prescription of aspirin.
After 9 years of observation was that the lowest risk of cancer was observed among the groups receiving higher doses of proton pump inhibitor. After taking into account information on receiving additional drugs outside the study Protocol was that patients receiving aspirin had a lower risk of developing severe dysplasia and esophageal cancer.
The study authors emphasize that the majority of elderly patients have to take aspirin or other nonsteroidal anti-inflammatory drugs for medical reasons. In connection with the carrying out true prospective, comparative study is becoming impossible for ethical reasons. However, the results of the conducted research it is still possible to conclude that aspirin has a preventive effect against cancer of the esophagus. This may be an important factor in the selection of therapy, as it is often elderly people in need of receiving antiplatelet agents, and are at risk of cancer.